Antihyperglycemic medications: A claims-based estimate of first-line therapy use prior to initialization of second-line medications

Yi Ju Tseng, Gregory Steinberg, Kathe P. Fox, Joanne Armstrong, Kenneth D. Mandl

研究成果: 雜誌貢獻期刊論文同行評審

5 引文 斯高帕斯(Scopus)

摘要

OBJECTIVE The American Diabetes Association recommends metformin as first-line therapy for type 2 diabetes. However, nonadherence to antihyperglycemic medication is common, and a clinician could confuse nonadherence with pharmacologic failure, potentially leading to premature prescribing of second-line therapies. We measured metformin use prior to second-line therapy initialization. RESEARCH DESIGN AND METHODS This retrospective cross-sectional study used unidentifiable member claims data from individuals covered from 2010 to 2015 by Aetna, a U.S. health benefits company. Beneficiaries with two physician claims or one hospitalization with a type 2 diabetes diagnosis were included. Recommended use of metformin was measured by the proportion of days covered over 60 days. Through sensitivity analysis, we varied estimates of the percentage of beneficiaries who used low-cost generic prescription medication programs. RESULTS A total of 52,544 individuals with type 2 diabetes were eligible. Of 22,956 patients given second-line treatment, only 1,875 (8.2%) had evidence of recommended use of metformin in the prior 60 days, and 6,441 (28.0%) had no prior claims evidence of having taken metformin. At the top range of sensitivity, only 49.5% patients could have had recommended use. Patients were more likely to be given an additional second-line antihyperglycemic medication or insulin if they were given their initial second-line medication without evidence of recommended use of metformin (P < 0.001). CONCLUSIONS Despite published guidelines, second-line therapy often is initiatedwithout evidence of recommended use of first-line therapy. Apparent treatment failures, whichmay in fact be attributable to nonadherence to guidelines, are common. Point-of-care and population-level processes are needed tomonitor and improve guideline adherence.

原文???core.languages.en_GB???
頁(從 - 到)1500-1505
頁數6
期刊Diabetes Care
40
發行號11
DOIs
出版狀態已出版 - 1 11月 2017

指紋

深入研究「Antihyperglycemic medications: A claims-based estimate of first-line therapy use prior to initialization of second-line medications」主題。共同形成了獨特的指紋。

引用此